Prothena Corporation plc - Ordinary Shares (NQ:PRTA)

8.840 +0.230 (+2.67%)

Delayed Quote Updated: 4:00 PM EDT, Oct 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Prothena Corporation plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

What 4 Analyst Ratings Have To Say About Prothena Corp ↗

August 28, 2025

Via Benzinga

Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program

August 27, 2025

From Prothena Corporation plc

Via Business Wire

Novo Nordisk Commits To Advancing Prothena Corp-Developed Drug Into Late Stage Trial: Retail Turns Hopeful ↗

August 06, 2025

Coramitug was initially developed by Prothena and was acquired by Novo Nordisk in July 2021.

Via Stocktwits

Topics Earnings

Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

August 06, 2025

From Prothena Corporation plc

Via Business Wire

9 Analysts Assess Prothena Corp: What You Need To Know ↗

August 05, 2025

Via Benzinga

Earnings Scheduled For August 4, 2025 ↗

August 04, 2025

Via Benzinga

A Glimpse of Prothena Corp's Earnings Potential ↗

August 01, 2025

Via Benzinga

Prothena Q2 Revenue Drops 97% ↗

August 05, 2025

Via The Motley Fool

Topics Intellectual Property

Prothena Reports Second Quarter 2025 Financial Results and Business Highlights

August 04, 2025

From Prothena Corporation plc

Via Business Wire

Prothena to Report Second Quarter 2025 Financial Results on August 4

July 28, 2025

From Prothena Corporation plc

Via Business Wire

8 Analysts Assess Prothena Corp: What You Need To Know ↗

June 20, 2025

Via Benzinga

Prothena Shares Get A Boost After Company Slashes Workforce, Lowers 2025 Cash Burn Forecast ↗

June 20, 2025

The biotech firm expects to end 2025 with nearly $300 million in cash as it pivots to focus on its Alzheimer’s and Parkinson’s pipeline.

Via Stocktwits

Topics Workforce

Prothena Announces Corporate Restructuring

June 18, 2025

From Prothena Corporation plc

Via Business Wire

Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

June 16, 2025

From Prothena Corporation plc

Via Business Wire

Williams Companies To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

May 28, 2025

Via Benzinga

Here are the top movers in Tuesday's session. ↗

May 27, 2025

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

May 27, 2025

Via Benzinga

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

May 27, 2025

Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.

Via Chartmill

There are notable gap-ups and gap-downs in today's session. ↗

May 27, 2025

In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down.

Via Chartmill

PTC Therapeutics To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

May 27, 2025

Via Benzinga

Expert Outlook: Prothena Corp Through The Eyes Of 5 Analysts ↗

May 27, 2025

Via Benzinga

Stay updated with the stocks that are on the move in today's pre-market session. ↗

May 27, 2025

Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Via Chartmill

PDD Holdings Posts Weak Results, Joins EHang Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

May 27, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

May 27, 2025

Via Benzinga

Why Is Prothena Stock Trading Lower On Tuesday? ↗

May 27, 2025

Prothena halts birtamimab development after Phase 3 trial fails to meet endpoints in AL amyloidosis patients; cost cuts and new focus expected.

Via Benzinga

US Stocks Likely To Open Higher After S&P 500's Four-Day Fall: 'Market Is Risk-Off,' Says Expert ↗

May 27, 2025

U.S. stock futures rose on Tuesday after closing lower for the week on Friday. Futures of benchmark indices were trading higher in premarket.

Via Benzinga

Topics Stocks

Why E2open Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket ↗

May 27, 2025

Via Benzinga

These stocks are moving in today's after hours session ↗

May 26, 2025

As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Via Chartmill

12 Health Care Stocks Moving In Friday's After-Market Session ↗

May 23, 2025

Via Benzinga

Top movers in Friday's after hours session ↗

May 23, 2025

As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.